Ascendis Pharma A/SASNDNASDAQ
Loading
EBITDA Margin Over TimeExpanding
Percentile Rank85
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

Latest
-16.47%
↑ 99% vs avg
Percentile
P85
Within normal range
Streak
5 yr
Consecutive growthExpanding
Average
-2357.76%
Historical baseline
PeriodValueYoY Change
2025-16.47%+79.4%
2024-79.76%+48.3%
2023-154.16%+85.1%
2022-1034.07%+77.9%
2021-4688.12%+20.1%
2020-5865.21%-272.9%
2019-1572.79%-10.8%
2018-1419.32%+80.2%
2017-7181.96%-358.7%
2016-1565.78%-